Mano Michael 4

What Happened
Mano Michael, EVP, Chief Legal Officer & Secretary of Karyopharm Therapeutics Inc. (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The award is recorded on the Form 4 as an acquisition at $0.00 per share (total reported cash paid = $0). This is an equity award (grant) rather than a purchase or sale.

Key Details

• Transaction date: 2026-01-31; Form 4 filed 2026-02-03 (no late filing indicated in the filing).
• Transaction type/code: A = Award/Grant (RSUs). Reported acquisition price: $0.00.
• Shares granted: 32,415 RSUs (convert one-for-one to common stock upon vesting).
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: RSUs vest 50% on January 31, 2027 and the remaining 50% on January 31, 2028 (per the company’s 2022 Equity Incentive Plan, as amended).

Context
RSU grants are compensation and do not require an upfront cash outlay by the insider; they only convert to actual shares when they vest. The reported $0 acquisition price on Form 4 is standard for RSU awards and does not reflect future market value, which depends on KPTI’s stock price at vesting.